KRAS and lung cancer: Various efforts to specifically target KRAS with farnesyl transferase inhibitors (FTIs), which block RAS membrane attachment and RAS signaling, have failed to show a significant enzyme inhibitory activity needed for clinical activity, which may explain the limited therapeutic effect of FTIs in phase II lung cancer trials [6].